[go: up one dir, main page]

EG24071A - Injectable quinolone formulations - Google Patents

Injectable quinolone formulations

Info

Publication number
EG24071A
EG24071A EG113496A EG113496A EG24071A EG 24071 A EG24071 A EG 24071A EG 113496 A EG113496 A EG 113496A EG 113496 A EG113496 A EG 113496A EG 24071 A EG24071 A EG 24071A
Authority
EG
Egypt
Prior art keywords
injectable
quinolone
formulations
quinolone formulations
injectable quinolone
Prior art date
Application number
EG113496A
Other languages
English (en)
Inventor
Wayne A Boettner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24071(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG24071A publication Critical patent/EG24071A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EG113496A 1995-12-21 1996-12-17 Injectable quinolone formulations EG24071A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
EG24071A true EG24071A (en) 2008-05-11

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
EG113496A EG24071A (en) 1995-12-21 1996-12-17 Injectable quinolone formulations

Country Status (42)

Country Link
US (1) US5811130A (fr)
EP (1) EP0868183B1 (fr)
JP (1) JP3416145B2 (fr)
KR (1) KR100402570B1 (fr)
CN (1) CN1104899C (fr)
AP (1) AP706A (fr)
AR (1) AR005147A1 (fr)
AT (1) ATE212551T1 (fr)
AU (1) AU709474B2 (fr)
BG (1) BG63933B1 (fr)
BR (1) BR9612230A (fr)
CA (1) CA2239352C (fr)
CO (1) CO4480098A1 (fr)
CZ (1) CZ293747B6 (fr)
DE (1) DE69618987T2 (fr)
DK (1) DK0868183T3 (fr)
DZ (1) DZ2146A1 (fr)
EG (1) EG24071A (fr)
ES (1) ES2167609T3 (fr)
GT (1) GT199600098A (fr)
HR (1) HRP960607B1 (fr)
HU (1) HU227918B1 (fr)
IL (1) IL124454A (fr)
IS (1) IS2010B (fr)
MA (1) MA24035A1 (fr)
MX (1) MX9805026A (fr)
MY (1) MY117109A (fr)
NO (1) NO315734B1 (fr)
NZ (2) NZ501160A (fr)
OA (1) OA10697A (fr)
PE (1) PE25798A1 (fr)
PL (1) PL186795B1 (fr)
PT (1) PT868183E (fr)
RS (1) RS49523B (fr)
RU (1) RU2141827C1 (fr)
SI (1) SI0868183T1 (fr)
SK (1) SK284412B6 (fr)
TN (1) TNSN96163A1 (fr)
TW (1) TW449475B (fr)
UA (1) UA56151C2 (fr)
WO (1) WO1997023217A1 (fr)
ZA (1) ZA9610780B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
WO2004002533A1 (fr) * 2002-06-26 2004-01-08 Pharmacia Corporation Formulation de parecoxib liquide stable administree par voie parenterale
ZA200700844B (en) * 2004-07-02 2009-07-29 Daiichi Seiyaku Co Quinolone-containing medicinal composition
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PL1901749T3 (pl) * 2005-05-18 2017-04-28 Horizon Orphan Llc Fluorochinolony w aerozolu i ich zastosowania
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
BRPI0707641A2 (pt) * 2006-02-10 2011-05-10 Pari Pharma Gmbh antibiàticos nebulizados para terapia de inalaÇço
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
CA2739897C (fr) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Formulations a base de fluoroquinolone sous forme d'aerosol pour une pharmacocinetique amelioree
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
EP2473170B1 (fr) 2009-09-04 2019-06-19 Horizon Orphan LLC Utilisation de lévofloxacine en aérosol pour traiter la fibrose kystique
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
EP3305295A4 (fr) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. Médicament aqueux
EP3305294A4 (fr) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. Médicament aqueux
WO2016195021A1 (fr) 2015-06-02 2016-12-08 杏林製薬株式会社 Formulation liquide aqueuse
PE20191462A1 (es) * 2017-02-13 2019-10-16 Bayer Animal Health Gmbh Composicion liquida que contiene pradofloxacina
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US523505A (en) * 1894-07-24 Island
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
WO1991009525A1 (fr) * 1989-12-29 1991-07-11 Abbott Laboratories Complexes acide-ion metal-acide carboxylique de quinolone
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
DE69102900T3 (de) * 1990-02-14 1998-04-09 Otsuka Pharma Co Ltd Brausemischung, deren Herstellung sowie Verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
DK0868183T3 (da) 2002-03-25
IL124454A (en) 2003-10-31
HU227918B1 (en) 2012-06-28
CO4480098A1 (es) 1997-07-09
RS49523B (sr) 2006-10-27
DE69618987D1 (de) 2002-03-14
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
NO982842L (no) 1998-06-19
JP3416145B2 (ja) 2003-06-16
YU69096A (sh) 1999-06-15
NO315734B1 (no) 2003-10-20
RU2141827C1 (ru) 1999-11-27
HRP960607B1 (en) 2002-06-30
NO982842D0 (no) 1998-06-19
CZ193098A3 (cs) 1999-05-12
AP9600898A0 (en) 1997-01-31
EP0868183B1 (fr) 2002-01-30
KR100402570B1 (ko) 2003-12-18
CN1104899C (zh) 2003-04-09
KR19990076617A (ko) 1999-10-15
UA56151C2 (uk) 2003-05-15
HUP9903726A2 (hu) 2000-04-28
BG102542A (en) 1999-06-30
OA10697A (en) 2001-05-04
BG63933B1 (bg) 2003-07-31
CA2239352C (fr) 2002-06-04
MY117109A (en) 2004-05-31
DZ2146A1 (fr) 2002-10-23
TNSN96163A1 (fr) 2005-03-15
WO1997023217A1 (fr) 1997-07-03
PE25798A1 (es) 1998-05-21
IL124454A0 (en) 1998-12-06
HRP960607A2 (en) 1998-06-30
AU7328996A (en) 1997-07-17
CA2239352A1 (fr) 1997-07-03
GT199600098A (es) 1998-06-12
IS4755A (is) 1998-05-25
JPH11501331A (ja) 1999-02-02
NZ501160A (en) 2001-10-26
SK80798A3 (en) 1999-09-10
PT868183E (pt) 2002-06-28
MA24035A1 (fr) 1997-07-01
SK284412B6 (sk) 2005-03-04
CZ293747B6 (cs) 2004-07-14
ATE212551T1 (de) 2002-02-15
ZA9610780B (en) 1998-06-22
CN1205636A (zh) 1999-01-20
PL328001A1 (en) 1999-01-04
BR9612230A (pt) 1999-07-13
US5811130A (en) 1998-09-22
SI0868183T1 (en) 2002-04-30
EP0868183A1 (fr) 1998-10-07
MX9805026A (es) 1998-09-30
HUP9903726A3 (en) 2001-01-29
IS2010B (is) 2005-05-13
PL186795B1 (pl) 2004-02-27
AR005147A1 (es) 1999-04-14
NZ320545A (en) 2000-03-27
DE69618987T2 (de) 2002-11-21
TW449475B (en) 2001-08-11
ES2167609T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
EG24071A (en) Injectable quinolone formulations
EG24118A (en) Pharmaceutical compositions
IL118004A0 (en) Vaccine compositions
IL117249A0 (en) Vaccine compositions
GB9616672D0 (en) Pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
GB9622681D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9623962D0 (en) Pharmaceutical composition
GB9610136D0 (en) Pharmaceutical compositions
GB9618376D0 (en) Pharmaceutical compositions
GB9509291D0 (en) Formulations
GB9603942D0 (en) Pharmaceutical compositions
GB9606586D0 (en) Pharmaceutical compositions
SI0941095T1 (en) Improved pharmaceutical compositions
GB9624115D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9510349D0 (en) Formulations
GB9508144D0 (en) Formulations
GB9620048D0 (en) Pharmaceutical composition
GB9626185D0 (en) Pharmaceutical composition
ZA962792B (en) Pharmaceutical composition
GB9615627D0 (en) Pharmaceutical composition
GB9611530D0 (en) Pharmaceutical composition